Latisse Calls For Fda Regulation Of Competitors
By Anna K. Fryxell |
Ever since Latisse hit the scene, it seems like nearly every cosmetics company has come out with their own version of a lash-enhancing serum. From inexpensive to ultra pricey versions, there's no end in sight to how many brands will exist. Or could there be?
Allergan, Inc., the company behind Latisse, and Botox for that matter, has been lobbying for the past few years to even the playing field for its competitors. Their goal? To make rival products currently classified as cosmetics be classified as drugs just like Latisse.
The problem with competing products labeled as cosmetics instead of drugs, is that the FDA has no authority to regulate the ingredients being used or recall products. And even though the FDA does have the power to ban dangerous substances, they rarely do.
Currently, the FDA defines anything that “treats or alters the structure or function of the body” as a drug. Allergan is specifically asking that any product containing prostaglandin analogs (PGAs), the active ingredient in Latisse, be classified as a drug. The issue is a top priority for the company, who are pushing for the FDA to have a bigger involvement when it comes to the safety of cosmetics.
Sunscreen Regulation Debate: Is the FDA Doing the Right Thing?
Mercury Found in Face Creams Sold Across U.S.